Publications by authors named "Mary E Klein Dooley"
Clin Cancer Res
February 2024
Article Synopsis
- The research focused on CDK4/6 inhibitors, specifically exploring how cellular senescence affects tumor growth in humans and its implications for cancer treatment.
- A phase II clinical trial involving 30 patients with dedifferentiated liposarcoma tested the CDK4/6 inhibitor abemaciclib, demonstrating a median progression-free survival of 33 weeks and a good safety profile.
- The study identified ANGPTL4 as a key factor in cell senescence, highlighting its role in immune response and suggesting that combining senolytics with abemaciclib could enhance treatment effectiveness in certain patients.
